@article{9f3ac9c6efce4ce797707a4fb85ed0f8,
title = "Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample",
abstract = "Aim: Investigating biological processes in at-risk individuals may help elucidate the aetiological mechanisms underlying psychosis development, refine prediction models and improve intervention strategies. This study examined the associations between sleep disturbances, chronotype, depressive and psychotic symptoms in individuals at ultra-high risk for psychosis. Methods: A sample of 81 ultra-high risk patients completed clinical interviews and self-report assessments of chronotype and sleep during the Neurapro clinical trial. Mixed regression was used to investigate the cross-sectional associations between symptoms and sleep disturbances/chronotype. Results: Sleep disturbances were significantly associated with increased depressive and attenuated positive psychotic symptoms. Greater preference for eveningness was significantly associated with increased negative symptoms, but not with depressive or attenuated positive psychotic symptoms. Conclusion: Sleep disturbances and chronotype may impact the emerging psychopathology experienced by ultra-high risk individuals. Further, the preliminary relationship observed between greater preference for eveningness and negative symptoms offers a unique opportunity to treat negative symptoms through chronobiological approaches.",
keywords = "chronotype, negative symptoms, psychosis, sleep, ultra-high risk",
author = "Shetty, {Jashmina J.} and Christian Nicholas and Barnaby Nelson and McGorry, {Patrick D.} and Suzie Lavoie and Connie Markulev and Sch{\"a}fer, {Miriam R.} and Andrew Thompson and Yuen, {Hok Pan} and Yung, {Alison R.} and Nieman, {Dorien H.} and {de Haan}, Lieuwe and Amminger, {G. Paul} and Hartmann, {Jessica A.}",
note = "Funding Information: PDM reports receiving unrestricted research funding from AstraZeneca, Eli Lilly and Company, Janssen‐Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly and Company, Janssen‐Cilag, Pfizer, Bristol‐Myers Squibb, Roche Holding AG, and the Lundbeck Institute. The other authors declare no potential conflicts of interest. Funding Information: The authors thank all participants and their families. The Neurapro clinical trial was supported by grant 07TGF‐1102 from the Stanley Medical Research Institute, grant 566529 from the National Health and Medical Research Council (NHMRC) Australia (to PDM, ARY, and GPA) and a grant from the Colonial Foundation. PDM was supported by NHMRC Senior Principal Research Fellowship 1060996; GPA and ARY were supported by NHMRC Senior Research Fellowships 1080963 and 566593, respectively; and BN was supported by NHMRC Career Development Fellowship 1027532. JAH is supported by a University of Melbourne McKenzie Postdoctoral Fellowship. Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Australia, Ltd",
year = "2021",
month = dec,
doi = "https://doi.org/10.1111/eip.13112",
language = "English",
volume = "15",
pages = "1793--1798",
journal = "Early intervention in psychiatry",
issn = "1751-7885",
publisher = "Wiley",
number = "6",
}